Search
Close this search box.

E-chapters

Anti-cancer Immunotherapy

Back to top

References

  • Adams, G. P., and Weiner, L. M. (2005) Monoclonal antibody therapy of cancer. Nat Biotech 23, 1147–1157.
  • Allen, J. R., Harris, C. R., and Danishefsky, S. J. (2001) Pursuit of Optimal Carbohydrate-Based Anticancer Vaccines : Preparation of a Multiantigenic Unimolecular Glycopeptide Containing the Tn, MBr1, and Lewisy Antigens. J. Am. Chem. Soc. 123, 1890–1897.
  • Ashizawa, T., Miyata, H., Ishii, H., Oshita, C., Matsuno, K., Masuda, Y., Furuya, T., Okawara, T., Otsuka, M., Ogo, N., Asai, A., and Akiyama, Y. (2011) Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int. J. Oncol. 38, 1245–1252.
  • Astronomo, R. D., and Burton, D. R. (2010) Carbohydrate vaccines : developing sweet solutions to sticky situations ? Nat. Rev. Drug Discov. 9, 308–324.
  • Berti, F., and Adamo, R. (2013) Recent Mechanistic Insights on Glycoconjugate Vaccines and Future Perspectives. ACS Chem. Biol. 8, 1653–1663.
  • Bilodeau, M. T., Park, T. K., Hu, S., Randolph, J. T., Danishefsky, S. J., Livingston, P. O., and Zhang, S. (1995) Total Synthesis of a Human Breast Tumor Associated Antigen. J. Am. Chem. Soc. 117, 7840–7841.
  • Biswas, K., Coltart, D. M., and Danishefsky, S. J. (2002) Construction of carbohydrate-based antitumor vaccines : synthesis of glycosyl amino acids by olefin cross-metathesis. Tetrahedron Lett. 43, 6107–6110.
  • Buskas, T., Li, Y., and Boons, G.-J. (2004) The Immunogenicity of the Tumor-Associated Antigen Lewisy May Be Suppressed by a Bifunctional Cross-Linker Required for Coupling to a Carrier Protein. Chem. – A Eur. J. 10, 3517–3524.
  • Cecioni, S., Imberty, A., and Vidal, S. (2015) Glycomimetics versus Multivalent Glycoconjugates for the Design of High Affinity Lectin Ligands. Chem. Rev. 115, 525–561.
  • Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T., and Lucas, S. (2001) An Overview of the MAGE Gene Family with the Identification of All Human Members of the Family. Cancer Res. 61, 5544–5551.
  • Coley, W. B. (1893) The treatment of malignant tumours by repeated inoculations of erysipelas : with a report of ten original cases. Am. J. Med. Sci. 105, 487–511.
  • Corzana, F., Busto, J. H., García de Luis, M., Jiménez-Barbero, J., Avenoza, A., and Peregrina, J. M. (2009) The Nature and Sequence of the Amino Acid Aglycone Strongly Modulates the Conformation and Dynamics Effects of Tn Antigen’s Clusters. Chem. – A Eur. J. 15, 3863–3874.
  • Couzin-Frankel, J. (2013) Cancer Immunotherapy. Science (80-. ). 342, 1432–1433.
  • Dagan, R., Poolman, J., and Siegrist, C. A. (2010) Glycoconjugate vaccines and immune interference : A review. Vaccine 28, 5513–5523.
  • Danishefsky, S. J., and Bilodeau, M. T. (1996) Glycals in Organic Synthesis : The Evolution of Comprehensive Strategies for the Assembly of Oligosaccharides and Glycoconjugates of Biological Consequence. Angew. Chemie Int. Ed. English 35, 1380–1419.
  • Danishefsky, S. J., Behar, V., Randolph, J. T., and Lloyd, K. O. (1995) Application of the Glycal Assembly Method to the Concise Synthesis of Neoglycoconjugates of Ley and Leb Blood Group Determinants and of H-Type I and H-Type II Oligosaccharides. J. Am. Chem. Soc. 117, 5701–5711.
  • Devaud, C., John, L. B., Westwood, J. A., Darcy, P. K., and Kershaw, M. H. (2013) Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2, e25961.
  • Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., and Schiffman, K. (2002) Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines. J. Clin. Oncol. 20, 2624–2632.
  • Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., Robinson, M. R., Raffeld, M., Duray, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., Mavroukakis, S. A., White, D. E., and Rosenberg, S. A. (2002) Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science (80-. ). 298, 850–854.
  • Dziadek, S., Kowalczyk, D., and Kunz, H. (2005) Synthetic Vaccines Consisting of Tumor-Associated MUC1 Glycopeptide Antigens and Bovine Serum Albumin. Angew. Chemie Int. Ed. 44, 7624–7630.
  • Feng, D., Shaikh, A. S., and Wang, F. (2016) Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines. ACS Chem. Biol. 11, 850–863.
  • Ferguson, K. M. (2008) Structure-Based View of Epidermal Growth Factor Receptor Regulation. Annu. Rev. Biophys. 37, 353–373.
  • Fernández-Tejada, A., Brailsford, J., Zhang, Q., Shieh, J.-H., Moore, M. A. S., and Danishefsky, S. J. (2015) Total Synthesis of Glycosylated Proteins – Protein Ligation and Total Synthesis I (Liu, L., Ed.), pp 1–26. Springer International Publishing, Cham.
  • Finn, O. J. (2014) Vaccines for Cancer Prevention : A Practical and Feasible Approach to the Cancer Epidemic. Cancer Immunol. Res. 2, 708–713.
  • Floros, T., and Tarhini, A. A. (2015) Anticancer Cytokines : Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin. Oncol. 42, 539–548.
  • Gabius, H. J., and Roth, J. (2017) An introduction to the sugar code. Histochem. Cell Biol. 147, 111–117.
  • Gamblin, D. P., Scanlan, E. M., and Davis, B. G. (2009) Glycoprotein Synthesis : An Update. Chem. Rev. 109, 131–163.
  • Genbacev, O. D., Prakobphol, A., Foulk, R. A., Krtolica, A. R., Ilic, D., Singer, M. S., Yang, Z.-Q., Kiessling, L. L., Rosen, S. D., and Fisher, S. J. (2003) Trophoblast L-Selectin-Mediated Adhesion at the Maternal-Fetal Interface. Science (80-. ). 299, 405–408.
  • Gildersleeve, J. C., Oyelaran, O., Simpson, J. T., and Allred, B. (2008) Improved Procedure for Direct Coupling of Carbohydrates to Proteins via Reductive Amination. Bioconjug. Chem. 19, 1485–1490.
  • Gildersleeve, J. C., Wang, B., Achilefu, S., Tu, Z., and Xu, M. (2012) Glycan array analysis of the antigen repertoire targeted by tumor-binding antibodies. Bioorg. Med. Chem. Lett. 22, 6839–6843.
  • Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L. J., Musselli, C., Zhang, X.-F., Bencsath, K. P., Panageas, K. S., Chin, J., Hudis, C. A., Norton, L., Houghton, A. N., Livingston, P. O., and Danishefsky, S. J. (2001) Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate : A phase I trial. Proc. Natl. Acad. Sci. 98, 3270–3275.
  • Gulley, J. L., Madan, R. A., and Schlom, J. (2011) Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr. Oncol. 18, 150–157.
  • Guo, C., Manjili, M. H., Subjeck, J. R., Sarkar, D., Fisher, P. B., and Wang, X. Y. (2013) Therapeutic cancer vaccines. Past, present, and future. Adv. Cancer Res. 119, 421–475.
  • Hanisch, F.-G., and Müller, S. (2000) MUC1 : the polymorphic appearance of a human mucin. Glycobiology 10, 439–449.
  • Hardwick, N., and Chain, B. (2011) Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. Immunotherapy 3, 731–733.
  • Helling, F., Shang, A., Calves, M., Zhang, S., Ren, S., Yu, R. K., Oettgen, H. F., and Livingston, P. O. (1994) GD3 Vaccines for Melanoma : Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines. Cancer Res. 54, 197–203.
  • Herzenberg, L. A., Tokuhisa, T., and Herzenberg, L. A. (1980) Carrier-priming leads to hapten-specific suppression. Nature 285, 664–667.
  • Huang, X., Huang, L., Wang, H., and Ye, X.-S. (2004) Iterative One-Pot Synthesis of Oligosaccharides. Angew. Chemie Int. Ed. 43, 5221–5224.
  • Ian Storer, R., Aciro, C., and Jones, L. H. (2011) Squaramides : physical properties, synthesis and applications. Chem. Soc. Rev. 40, 2330–2346.
  • Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., Lillemoe, K. D., O’Reilly, S., Abrams, R. A., Pardoll, D. M., Cameron, J. L., and Yeo, C. J. (2001) Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer : A Phase I Trial of Safety and Immune Activation. J. Clin. Oncol. 19, 145–156.
  • Jegerlehner, A., Storni, T., Lipowsky, G., Schmid, M., Pumpens, P., and Bachmann, M. F. (2002) Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 32, 3305–3314.
  • Kagan, E., Ragupathi, G., Yi, S. S., Reis, C. A., Gildersleeve, J., Kahne, D., Clausen, H., Danishefsky, S. J., and Livingston, P. O. (2005) Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 54, 424–430.
  • Kaiser, A., Gaidzik, N., Westerlind, U., Kowalczyk, D., Hobel, A., Schmitt, E., and Kunz, H. (2009) A synthetic vaccine consisting of a tumor-associated sialyl-T NMUC1 tandem-repeat glycopeptide and tetanus toxoid : induction of a strong and highly selective immune response. Angew. Chemie – Int. Ed. 48, 7551–7555.
  • Kaltgrad, E., Sen Gupta, S., Punna, S., Huang, C.-Y., Chang, A., Wong, C.-H., Finn, M. G., and Blixt, O. (2007) Anti-Carbohydrate Antibodies Elicited by Polyvalent Display on a Viral Scaffold. ChemBioChem 8, 1455–1462.
  • Kantoff, W. P., Higano, S. C., Shore, D. N., Berger, R. E., Small, J. E., Penson, F. D., Redfern, H. C., Ferrari, C. A., Dreicer, R., Sims, B. R., Xu, Y., Frohlich, W. M., and Schellhammer, F. P. (2010) Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Engl. J. Med. 363, 411–422.
  • Kawashima, I., Kotani, M., Ozawa, H., Suzuki, M., and Tai, T. (1994) Generation of monoclonal antibodies specific for ganglioside lactones : Evidence of the expression of lactone on human melanoma cells. Int. J. Cancer 58, 263–268.
  • Kiessling, L. L., and Grim, J. C. (2013) Glycopolymer probes of signal transduction. Chem. Soc. Rev. 42, 4476–4491.
  • Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., and Ferrone, S. (2012) Immunotherapy of cancer in 2012. CA. Cancer J. Clin. 62, 309–335.
  • Kufe, D. W. (2009) Mucins in cancer : function, prognosis and therapy. Nat Rev Cancer 9, 874–885.
  • Kunz, H., and Birnbach, S. (1986) Synthesis ofO-Glycopeptides of the Tumor-Associated TN- and T-Antigen Type and Their Binding to Bovine Serum Albumin. Angew. Chemie Int. Ed. English 25, 360–362.
  • Kurosaka, A., Kitagawa, H., Fukui, S., Numata, Y., Nakada, H., Funakoshi, I., Kawasaki, T., Ogawa, T., Iijima, H., and Yamashina, I. (1988) A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAcα2→6GalNAc, in mucin-type glycoproteins. J. Biol. Chem. 263, 8724–8726.
  • Kurosaki, T., Kometani, K., and Ise, W. (2015) Memory B cells. Nat. Rev. Immunol. 15, 149–159.
  • Kwon, D. S., Gregorio, G., Bitton, N., Hendrickson, W. A., and Littman, D. R. (2002) DC-SIGN-Mediated Internalization of HIV Is Required for Trans-Enhancement of T Cell Infection. Immunity 16, 135–144.
  • Lau, S. K., Weiss, L. M., and Chu, P. G. (2004) Differential Expression of MUC1, MUC2, and MUC5AC in Carcinomas of Various SitesAn Immunohistochemical Study. Am. J. Clin. Pathol. 122, 61–69.
  • Lin, T. (2006) Structural genesis of the chemical addressability in a viral nano-block. J. Mater. Chem. 16, 3673–3681.
  • Livingston, P. O. (1995) Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides : From Whole Melanoma Cells to Ganglioside-KLH Conjugate Vaccines. Immunol. Rev. 145, 147–166.
  • Livingston, P. O., Natoli, E. J., Calves, M. J., Stockert, E., Oettgen, H. F., and Old, L. J. (1987) Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. 84, 2911–2915.
  • Livingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., and Ritter, G. (1994) Improved survival in stage III melanoma patients with GM2 antibodies : a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12, 1036–1044.
  • Lundquist, J. J., and Toone, E. J. (2002) The cluster glycoside effect. Chem. Rev. 102, 555–578.
  • Mammen, M., Choi, S.-K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems : implications for design and use of multivalent ligands and inhibitors. Angew. Chemie, Int. Ed. 37, 2755–2794.
  • Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., and Mellstedt, H. (2014) Therapeutic vaccines for cancer : an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524.
  • Miermont, A., Barnhill, H., Strable, E., Lu, X., Wall, K. A., Wang, Q., Finn, M. G., and Huang, X. (2008) Cowpea Mosaic Virus Capsid : A Promising Carrier for the Development of Carbohydrate Based Antitumor Vaccines. Chem. – A Eur. J. 14, 4939–4947.
  • Monsan, P., Remaud-Siméon, M., and André, I. (2010) Transglucosidases as efficient tools for oligosaccharide and glucoconjugate synthesis. Curr. Opin. Microbiol. 13, 293–300.
  • Morgan, R. A., Chinnasamy, N., Abate-Daga, D. D., Gros, A., Robbins, P. F., Zheng, Z., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G. Q., Hughes, M. S., Kammula, U. S., Miller, A. D., Hessman, C. J., Stewart, A. A., Restifo, N. P., Quezado, M. M., Alimchandani, M., Rosenberg, A. Z., Nath, A., Wang, T., Bielekova, B., Wuest, S. C., Nirmala, A., McMahon, F. J., Wilde, S., Mosetter, B., Schendel, D. J., Laurencot, C. M., and Rosenberg, S. A. (2013) Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151.
  • Mu, C., Despras, G., Lindhorst, T. K., Mu, C., and Mu, C. (2016) Organizing multivalency in carbohydrate recognition. Chem. Soc. Rev. 45, 3275–3302.
  • Nakada, H., Inoue, M., Numata, Y., Tanaka, N., Funakoshi, I., Fukui, S., Mellors, A., and Yamashina, I. (1993) Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128). Proc. Natl. Acad. Sci. U. S. A. 90, 2495–2499.
  • Nakamori, S., Ota, D. M., Cleary, K. R., Shirotani, K., and Irimura, T. (1994) MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106, 353–361.
  • Nath, S., and Mukherjee, P. (2017) MUC1 : a multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 20, 332–342.
  • Oyelaran, O., and Gildersleeve, J. C. (2010) Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray. Proteomics – Clin. Appl. 4, 285–294.
  • Parslow, A., Parakh, S., Lee, F.-T., Gan, H., and Scott, A. (2016) Antibody–Drug Conjugates for Cancer Therapy. Biomedicines 4, 14.
  • Partis, M. D., Griffiths, D. G., Roberts, G. C., and Beechey, R. B. (1983) Cross-linking of protein by ω-maleimido alkanoylN-hydroxysuccinimido esters. J. Protein Chem. 2, 263–277.
  • Puffer, E. B., Pontrello, J. K., Hollenbeck, J. J., Kink, J. A., and Kiessling, L. L. (2007) Activating B Cell Signaling with Defined Multivalent Ligands. ACS Chem. Biol. 2, 252–262.
  • Ragupathi, G., Cappello, S., Yi, S. S., Canter, D., Spassova, M., Bornmann, W. G., Danishefsky, S. J., and Livingston, P. O. (2002) Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 20, 1030–1038.
  • Ragupathi, G., Coltart, D. M., Williams, L. J., Koide, F., Kagan, E., Allen, J., Harris, C., Glunz, P. W., Livingston, P. O., and Danishefsky, S. J. (2002) On the power of chemical synthesis : Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Natl. Acad. Sci. 99, 13699–13704.
  • Ragupathi, G., Koide, F., Livingston, P. O., Cho, Y. S., Endo, A., Wan, Q., Spassova, M. K., Keding, S. J., Allen, J., Ouerfelli, O., Wilson, R. M., and Danishefsky, S. J. (2006) Preparation and Evaluation of Unimolecular Pentavalent and Hexavalent Antigenic Constructs Targeting Prostate and Breast Cancer : A Synthetic Route to Anticancer Vaccine Candidates. J. Am. Chem. Soc. 128, 2715–2725.
  • Ragupathi, G., Koide, F., Sathyan, N., Kagan, E., Spassova, M., Bornmann, W., Gregor, P., Reis, C. A., Clausen, H., Danishefsky, S. J., and Livingston, P. O. (2003) A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol. Immunother. 52, 608–616.
  • Ragupathi, G., Meyers, M., Adluri, S., Howard, L., Musselli, C., and Livingston, P. O. (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer 85, 659–666.
  • Ragupathi, G., Rao Koganty, R., Qiu, D., Lloyd, K. O., and Livingston, P. O. (1998) A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation : synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj. J. 15, 217–221.
  • Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J. T., and Alves, P. M. (2010) Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149–1176.
  • Scher, H. I., Eisenberger, M., D’Amico, A. V, Halabi, S., Small, E. J., Morris, M., Kattan, M. W., Roach, M., Kantoff, P., Pienta, K. J., Carducci, M. A., Agus, D., Slovin, S. F., Heller, G., Kelly, W. K., Lange, P. H., Petrylak, D., Berg, W., Higano, C., Wilding, G., Moul, J. W., Partin, A. N., Logothetis, C., and Soule, H. R. (2004) Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen : Recommendations From the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 22, 537–556.
  • Seeberger, P. H. (2015) The Logic of Automated Glycan Assembly. Acc. Chem. Res. 48, 1450–1463.
  • Slovin, S. F., Keding, S. J., and Ragupathi, G. (2005) Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 83, 418–428.
  • Slovin, S. F., Ragupathi, G., Musselli, C., Fernandez, C., Diani, M., Verbel, D., Danishefsky, S., Livingston, P., and Scher, H. I. (2005) Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine : clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54, 694–702.
  • Soares, M. M., Mehta, V., and Finn, O. J. (2001) Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection. J. Immunol. 166, 6555–6563.
  • Svennerholm, L. (1957) Quantitive estimation of sialic acids. Biochim. Biophys. Acta 24, 604–611.
  • Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita, H., Gejyo, F., Okumura, K., and Smyth, M. J. (2010) Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules. J. Immunol. 184, 5493–5501.
  • Tang, C.-K., and Apostolopoulos, V. (2008) Strategies used for MUC1 immunotherapy : preclinical studies. Expert Rev. Vaccines 7, 951–962.
  • Tangye, S. G., Ferguson, A., Avery, D. T., Ma, C. S., and Hodgkin, P. D. (2002) Isotype Switching by Human B Cells Is Division-Associated and Regulated by Cytokines. J. Immunol. 169, 4298–4306.
  • Therasse, P., Eisenhauer, E. A., and Verweij, J. (2017) RECIST revisited : A review of validation studies on tumour assessment. Eur. J. Cancer 42, 1031–1039.
  • Treanor, B. (2012) B-cell receptor : From resting state to activate. Immunology 136, 21–27.
  • Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., Signori, E., Honoki, K., Georgakilas, A. G., Amin, A., Helferich, W. G., Boosani, C. S., Guha, G., Ciriolo, M. R., Chen, S., Mohammed, S. I., Azmi, A. S., Keith, W. N., Bilsland, A., Bhakta, D., Halicka, D., Fujii, H., Aquilano, K., Ashraf, S. S., Nowsheen, S., Yang, X., Choi, B. K., and Kwon, B. S. (2015) Immune evasion in cancer : Mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35, S185–S198.
  • Walker, L. S. K. (2017) PD-1 and CTLA-4 : Two checkpoints, one pathway ? Sci. Immunol. 2.
  • Wang, Q., Kaltgrad, E., Lin, T., Johnson, J. E., and Finn, M. G. (2002) Natural Supramolecular Building Blocks. Chem. Biol. 9, 805–811.
  • Ward, S., Casey, D., Labarthe, M.-C., Whelan, M., Dalgleish, A., Pandha, H., and Todryk, S. (2002) Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51, 351–357.
  • Wong, H. H., Lemoine, N. R., and Wang, Y. (2010) Oncolytic Viruses for Cancer Therapy : Overcoming the Obstacles. Viruses 2, 78–106.
  • Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O., and Livingston, P. O. (1997) Selection of tumor antigens as targets for immune attack using immunuhistochemistry : I. Focus on gangliosides. Int J Cancer 73, 42–49.
  • Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O., and Livingston, P. O. (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry : II. Blood group-related antigens. Int J Cancer 73, 50–56.
  • Zhu, J., Wan, Q., Lee, D., Yang, G., Spassova, M. K., Ouerfelli, O., Ragupathi, G., Damani, P., Livingston, P. O., and Danishefsky, S. J. (2009) From Synthesis to Biologics : Preclinical Data on a Chemistry Derived Anticancer Vaccine. J. Am. Chem. Soc. 131, 9298–9303.